Programmed death-1 (PD-1), also known as CD279, is a receptor for PDL1 and PDL2. PD-1 plays a crucial role in regulating peripheral tolerance and tumor immunity. PD-1 is expressed mainly on a subset of activated T cells, B cells and myeloid cells. Increased expression of PD-1 has been reported to be associated with poor prognosis in hepatocellular carcinoma (HCC) and renal cell carcinoma. PD-1 positivity has been found in angioimmunoblastic lymphoma, but not other subtypes of T-cell and B-cell non-Hodgkin lymphoma and classic Hodgkin lymphoma. PD-1 is a useful marker for angioimmunoblastic lymphoma.
Literature:
Manufacturer site:
PD-1 (PDCD1) (EP239)
Rabbit Monoclonal
Programmed death-1 (PD-1), also known as CD279, is a receptor for PDL1 and PDL2. PD-1 plays a crucial role in regulating peripheral tolerance and tumor immunity. PD-1 is expressed mainly on a subset of activated T cells, B cells and myeloid cells. Increased expression of PD-1 has been reported to be associated with poor prognosis in hepatocellular carcinoma (HCC) and renal cell carcinoma. PD-1 positivity has been found in angioimmunoblastic lymphoma, but not other subtypes of T-cell and B-cell non-Hodgkin lymphoma and classic Hodgkin lymphoma. PD-1 is a useful marker for angioimmunoblastic lymphoma.
Rabbit Monoclonal
Programmed death-1 (PD-1), also known as CD279, is a receptor for PDL1 and PDL2. PD-1 plays a crucial role in regulating peripheral tolerance and tumor immunity. PD-1 is expressed mainly on a subset of activated T cells, B cells and myeloid cells. Increased expression of PD-1 has been reported to be associated with poor prognosis in hepatocellular carcinoma (HCC) and renal cell carcinoma. PD-1 positivity has been found in angioimmunoblastic lymphoma, but not other subtypes of T-cell and B-cell non-Hodgkin lymphoma and classic Hodgkin lymphoma. PD-1 is a useful marker for angioimmunoblastic lymphoma.
